Macrogenics (MGNX) Achieves $15M Milestone Related to Gilead’s (GILD) Nomination of a Bispecific Research Program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/23/2026

1. USO
2. META
3. NVDA
4. SPY
5. DCOY
6. MSFT
7. VKTX
8. PRGS
9. PSKY
10. DGX

Go back to Macrogenics (MGNX) Achieves $15M Milestone Related to Gilead’s (GILD) Nomination of a Bispecific Research Program

MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program

September 5, 2023 7:00 AM EDT

ROCKVILLE, MD, Sept. 05, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that its partner, Gilead Sciences, Inc. (NASDAQ: GILD), nominated the first of two research programs, leveraging MacroGenics DART® and TRIDENT® platforms for generating bispecific antibodies. This nomination grants Gilead an exclusive option, upon achievement of a pre-defined preclinical milestone, to license worldwide rights to the research program.

Under the October 2022 agreement, MacroGenics will receive $15 million related to the nomination of a bispecific research program... More